Exubera Inhaled Insulin User Fee Deadline Is January 2006
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer and Sanofi-Aventis filed the Exubera NDA March 1; an early 2006 approval is based on a standard 10-month review. The companies expected to submit an NDA in 2001, but were delayed by pulmonary safety questions.